January 20, 2022
2 min watch
Save
VIDEO: ‘Exciting’ subcutaneous medication for hemophilia A, B
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Allyson Pishko, MD, MSCE, highlighted two studies from ASH Annual Meeting and Exposition that investigated fitusiran (Sanofi) as treatment for both hemophilia A and B.
“This medication is exciting because it’s subcutaneous, so we’re hoping that will increase compliance with the medication, and it’s also really important that it seems to work in patients who have inhibitors or who would not be expected to respond as well,” said Pishko, assistant professor of medicine at the University of Pennsylvania.
References
- Srivastava A, et al. LBA #3. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
- Young G, et al. Plenary Session #4. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Pishko reports receiving research funding from Sanofi Genzyme.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.